Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jason M Grayson

Showing results (41-50 of 48) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 48 results.
Journal of Immunology (Baltimore, Md. : 1950)|July 27, 2016
Targeting T Cell Bioenergetics by Modulating P-Glycoprotein Selectively Depletes Alloreactive T Cells To Prevent Graft-versus-Host DiseaseZachariah A McIver, Jason M Grayson, Benjamin N Coe, et al.
The Journal of Biological Chemistry|April 8, 2006
Activation of Tyk2 and Stat3 is required for the apoptotic actions of interferon-beta in primary pro-B cellsAna M Gamero, Ramesh Potla, Joanna Wegrzyn, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|March 17, 2009
Apolipoprotein A-I and its role in lymphocyte cholesterol homeostasis and autoimmunityAshley J Wilhelm, Manal Zabalawi, Jason M Grayson, et al.
Bioorganic & Medicinal Chemistry|June 16, 2016
Selective photodepletion of malignant T cells in extracorporeal photopheresis with selenorhodamine photosensitizersZachariah A McIver, Mark W Kryman, Young Choi, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 7, 2024
High-dimensional Immune Profiles and Machine Learning May Predict Acute Myeloid Leukemia Relapse Early following TransplantSamantha M Short, Mildred D Perez, Alexis E Morse, et al.
Clinical Lung Cancer|August 2, 2024
Mutations Associated With High-Grade irAEs in NSCLC Patients Receiving ImmunotherapiesMargaret R Smith, Yuezhu Wang, Caroline B Dixon, et al.
Blood Advances|November 22, 2024
MRD-driven phase 2 study of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myelomaManisha Bhutani, Myra Robinson, David Foureau, et al.
Cancer Research|September 9, 2024
Targeting NTRK1 Enhances Immune Checkpoint Inhibitor Efficacy in NTRK1 Wild-Type Non-Small Cell Lung CancerMargaret R Smith, Caroline B Dixon, Yuezhu Wang, et al.
Pageof 5

Showing results (41-50 of 48) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 48 results.
Journal of Immunology (Baltimore, Md. : 1950)|July 27, 2016
Targeting T Cell Bioenergetics by Modulating P-Glycoprotein Selectively Depletes Alloreactive T Cells To Prevent Graft-versus-Host DiseaseZachariah A McIver, Jason M Grayson, Benjamin N Coe, et al.
The Journal of Biological Chemistry|April 8, 2006
Activation of Tyk2 and Stat3 is required for the apoptotic actions of interferon-beta in primary pro-B cellsAna M Gamero, Ramesh Potla, Joanna Wegrzyn, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|March 17, 2009
Apolipoprotein A-I and its role in lymphocyte cholesterol homeostasis and autoimmunityAshley J Wilhelm, Manal Zabalawi, Jason M Grayson, et al.
Bioorganic & Medicinal Chemistry|June 16, 2016
Selective photodepletion of malignant T cells in extracorporeal photopheresis with selenorhodamine photosensitizersZachariah A McIver, Mark W Kryman, Young Choi, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 7, 2024
High-dimensional Immune Profiles and Machine Learning May Predict Acute Myeloid Leukemia Relapse Early following TransplantSamantha M Short, Mildred D Perez, Alexis E Morse, et al.
Clinical Lung Cancer|August 2, 2024
Mutations Associated With High-Grade irAEs in NSCLC Patients Receiving ImmunotherapiesMargaret R Smith, Yuezhu Wang, Caroline B Dixon, et al.
Blood Advances|November 22, 2024
MRD-driven phase 2 study of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myelomaManisha Bhutani, Myra Robinson, David Foureau, et al.
Cancer Research|September 9, 2024
Targeting NTRK1 Enhances Immune Checkpoint Inhibitor Efficacy in NTRK1 Wild-Type Non-Small Cell Lung CancerMargaret R Smith, Caroline B Dixon, Yuezhu Wang, et al.
Pageof 5